Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ACIPHEX

« Back to Dashboard
Aciphex is a drug marketed by Eisai Inc and is included in two NDAs. It is available from seven suppliers.

The generic ingredient in ACIPHEX is rabeprazole sodium. There are twenty-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rabeprazole sodium profile page.

Summary for Tradename: ACIPHEX

Suppliers / Packagers: see list15
2013 Sales:$683,359,000

Pharmacology for Tradename: ACIPHEX

Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors

Clinical Trials for: ACIPHEX

Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Status: Completed Condition: Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin

Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding
Status: Recruiting Condition: Nonvariceal Upper Gastrointestinal Bleeding

Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers
Status: Terminated Condition: Peptic Ulcer Hemorrhage

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Status: Completed Condition: Heartburn

A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury
Status: Completed Condition: Osteoarthritis; Arthritis, Rheumatoid; Dyspepsia

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Status: Completed Condition: Heartburn

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection
Status: Completed Condition: Early Gastric Adenocarcinoma; Adenocarcinoma, Tubular

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers
Status: Completed Condition: Gastroesophageal Reflux

A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers
Status: Completed Condition: Healthy

Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection
Status: Completed Condition: Helicobacter Pylori Infection

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973-001May 29, 2002DISCNNo<disabled><disabled>
Eisai Inc
rabeprazole sodium
CAPSULE, DELAYED RELEASE;ORAL204736-001Mar 26, 2013RXNo<disabled><disabled>
Eisai Inc
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973-002Aug 19, 1999RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn